Chronic Myeloid Leukemia Clinical Trials in Houston, Texas
8 recruitingHouston, Texas
Showing 1–8 of 8 trials
Recruiting
Phase 1
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center30 enrolled1 locationNCT06401603
Recruiting
Phase 2
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Chronic Myeloid Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT06817720
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Phase 1
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enliven Therapeutics250 enrolled45 locationsNCT05304377
Recruiting
Phase 2
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Chronic Myeloid Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT06236724
Recruiting
Phase 1Phase 2
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Chronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic Phase
Terns, Inc.180 enrolled54 locationsNCT06163430
Recruiting
Phase 2
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Chronic Myeloid LeukemiaChronic Myeloid Leukemia in RemissionChronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
Baylor College of Medicine100 enrolled4 locationsNCT04626024
Recruiting
Phase 3
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Chronic Myeloid LeukemiaCMLCML, Chronic Phase
Ascentage Pharma Group Inc.285 enrolled1 locationNCT06423911